(June 23, 2017) A clinical trial published in the Journal of Clinical Oncology focused on a largely understudied area of cancer survivorship: chemotherapy-induced peripheral neuropathy (CIPN) in women. Forty seven percent of the 512 women in the trial reported CIPN an average of 6 years after their treatment ended. Symptoms of CIPN reported during the … Continued
(June 1, 2017) A study, published last month in Gynecologic Oncology, focused on an area of ovarian cancer that is rarely talked about: the quality of life (QOL) for long term survivors of advanced stage ovarian cancer. Woman surviving 8.5 years or longer, who had anywhere from 0 recurrences to multiple recurrences, were given surveys … Continued
(May 25, 2017) A retrospective study, published earlier this month in Obstetrics & Gynecology, looked at when women with ovarian cancer developed blood clots. One in four women diagnosed with ovarian cancer develop a blood clot, but more specifically, over eleven percent of those who developed a blood clot did so during neoadjuvant chemotherapy. Women … Continued
(May 22, 2017) A recent study from the Netherlands found that a combination of cognitive behavior therapies had a positive effect on FCR, or Fear of Cancer Recurrence. Eighty-eight cancer survivors, including breast, prostate, and colorectal cancers, were divided into either a control group, which received usual care, or the therapy group. The participants that received … Continued
(May 2, 2017) A study, published in Gynecologic Oncology, revealed the importance of tumor antigen NY-ESO-1 for ovarian cancer patients. This tumor antigen, although not normally found in healthy cells, is very prevalent in tumors such as epithelial ovarian cancers. Over the course of the 14 year study, Roswell Park tested 1,000 ovarian cancer patients … Continued
(April 26, 2017) A study recently published in Cancer evaluates the effect that cediranib, a drugs that stops the growth of new blood vessels, has on a patient’s quality of life (QOL) when used as maintenance therapy. Previous studies have shown that, for patients with relapsed epithelial ovarian cancer, cediranib used as maintenance therapy can … Continued
(April 25, 2017) Researchers from Roswell Park Cancer Institute used data from 15 different studies that were part of the Ovarian Cancer Association Consortium, partially funded by OCRFA, to examine the relationship between epithelial ovarian cancer and hypertension, heart disease, diabetes, and the medications associated with those diseases. After reviewing over 7,600 cases, it was … Continued
A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2 mutation carriers with EOC. Researchers, including former OCRFA grantee and current OCRFA Scientific Advisory Committee Member Andrew Berchuck, looked at data from 25,509 EOC cases … Continued
(April 21, 2017) Endometriosis, a condition where the tissue that lines the inside of the uterus grows outside the uterus, has been found to be associated with an increased risk of ovarian cancer. The lives, habits, and medical histories of over 116,000 registered nurses were evaluated by the Nurses’ Health Study II for 18 years, … Continued
(April 20, 2017) Researchers from the National Cancer Institute assessed trends in the receipt of guideline care and 2-year cause-specific survival for women diagnosed with ovarian cancer. The study included 6427 women diagnosed in 2002 and in 2011. • The adjusted rate of women who received stage-appropriate surgery, 48%, was unchanged from 2002 to 2011. … Continued
(April 7, 2017) A major new study published in Science claims that the reason why many people get cancer is simply just bad luck. It’s normal for people to seek a reason when someone develops cancer (did he smoke? Was it hereditary?), and certainly lifestyle factors can play a major role in the development of … Continued
(March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib is the first PARP inhibitor to be approved … Continued
Get email updates about research news, action alerts, and ways to join the fight.
